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GlycoproteinThe Epstein–Barr virus (EBV) glycoprotein 42 (gp42) is a type II membrane protein essential for entry into
B cells but inhibits entry into epithelial cells. X-ray crystallography suggests that gp42 may form dimers
when bound to human leukocyte antigen (HLA) class II receptor (Mullen et al., 2002) or multimerize
when not bound to HLA class II (Kirschner et al., 2009). We investigated this self-association of gp42 using
several different approaches. We generated soluble mutants of gp42 containing mutations within the self-
association site and found that these mutants have a defect in fusion. The gp42 mutants bound to gH/gL
and HLA class II, but were unable to bind wild-type gp42 or a cleavage mutant of gp42. Using puriﬁed
gp42, gH/gL, and HLA, we found these proteins associate 1:1:1 by gel ﬁltration suggesting that gp42
dimerization or multimerization does not occur or is a transient event undetectable by our methods.nzyme-linked immunosorbent
g, microgram; V, volts; h, hour.
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Epstein–Barr virus (EBV), amember of the humanγ-herpesvirus, is a
large DNA virus infecting the majority of the adult population
worldwide. EBV predominantly infects B cells and epithelial cells. EBV
is transmitted via the saliva, enters the host via the oral epithelium and
subsequently infects human leukocyte antigen (HLA) class II expressing
B cells where it establishes a lifelong latent infection (Rickinson and
Kieff, 2007). Primary infection during early childhood is relatively
benign but during adulthood infectious mononucleosis can result.
Signiﬁcantly, EBV has been associated with several human B cell
malignancies, including endemic Burkitt's Lymphoma (BL), Hodgkin's
Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL), as well as
epithelial malignancies such as nasopharyngeal carcinoma, oral hairy
leukoplakia and gastric carcinoma (Bieging et al., 2010; Longnecker,
1998;RickinsonandKieff, 2007; Takada, 2001; ThompsonandKurzrock,
2004;Wei and Sham, 2005). Immunodeﬁcient patients, including those
withAIDS and those undergoing organ transplant and cancer treatment,
are particularly at risk for developing EBV associated lymphoprolifera-
tive diseases (Rickinson and Kieff, 2007).EBV attaches to B cells via viral glycoprotein gp350 and complement
receptor type 2 (CR2/CD21) (Fingeroth et al., 1984; Nemerow et al.,
1987; Tanner et al., 1987). Following attachment, glycoprotein 42
(gp42) interactswith its receptor, human leukocyte antigen (HLA) class
II (DR,DPandmostDQ forms) (Haanet al., 2000; Li et al., 1997;McShane
et al., 2003; Spriggs et al., 1996). It has beenhypothesized thatbindingof
gp42 to HLA class II causes a conformational change in gp42 triggering
the core fusion machinery of gH/gL and gB to mediate fusion between
the viral envelope and a cellularmembrane (Kirschner et al., 2009). EBV
entry into epithelial cells occurs by a different mechanism since HLA
class II is not typically expressed on epithelial cells and soluble gp42
promotes B cell fusion but inhibits epithelial cell fusion. Interestingly,
recent studies have shown that CR2/CD21 is expressed on tonsilar
epithelial cells indicating that, in some cases, EBV attachment to
epithelial cells may be similar to B cells (Jiang et al., 2008). Finally,
integrins have been found to serve as gH/gL receptors, allowing efﬁcient
EBV entry into epithelial cells independent of CR2/CD21 andHLA class II
(Chesnokova et al., 2009). The use of different glycoprotein–receptor
combinations to enter epithelial and B cells allows EBV to regulate cell
tropism. EBV virions exiting B cells contain less gp42 and more
efﬁciently infect epithelial cells, whereas virions exiting epithelial cells
contain more gp42 and more efﬁciently infect B cells (Borza and Hutt-
Fletcher, 2002).
gp42, encoded in the BZLF2 open reading frame, is a type II
membrane glycoprotein, containing a short cytoplasmic tail, a
transmembrane domain and an extracellular domain. In infected
B cells, two forms of gp42 are produced: a full length 223 amino acid
transmembrane protein and a truncated soluble form (Ressing et al.,
2005). Soluble gp42 is generated in the endoplasmic reticulum
123C.L. Rowe et al. / Virology 415 (2011) 122–131posttranslationally by host proteases, which cleave at amino acids
40–42, downstream of the transmembrane spanning domain (amino
acids 9–22) (Ressing et al., 2005). Due to inefﬁcient cleavage,
however, the full length transmembrane form is also produced
(Ressing et al., 2005). Both forms of gp42 bind gH/gL and HLA class II
and both forms are present in gH–gL–gp42 complexes (Kirschner
et al., 2006, 2007; Liu et al., 2010; McShane et al., 2003; Ressing et al.,
2005). Deletion of the cleavage site (residues 37–41) renders gp42
unable to mediate fusion, suggesting soluble gp42 is the functional
form required for B cell fusion (Sorem et al., 2009).
The HLA binding site residues of gp42 lie within the C-terminus
(residues 94–221) which contains a canonical C-type lectin domain
(CTLD). The CTLD of gp42 is structurally similar to that of natural killer
(NK) cell receptors, however gp42 does not utilize the “canonical”
binding site to bind HLA class II. Instead, this domain of gp42
constitutes a hydrophobic pocket and the HLA binding site lies outside
of this pocket (Mullen et al., 2002; Shaw et al., 2010). Signiﬁcantly,
soluble gp42 can inhibit HLA class II-restricted antigen presentation to
T cells and block TCR-class II peptide interactions by steric hindranceFig. 1. Putative multimer/dimer formation of gp42. Mutated gp42 residues F88 (yellow) a
(A) gp42 multimer packing in the crystal lattice (PDB ID 3FD4). Residues 87–93 (green) in
gp42 crystal structure contains two molecules in the asymmetric unit, chain A (residues 83
class II complex dimer formation in the crystal structure (PDB ID 1KG0). Residues 87–94 of t
residue F88 (yellow and labeled) of one gp42molecule docks into a shallow hydrophobic poc
labeled). gp42 molecules are colored wheat, HLA molecules are colored gray. The N-termin(Ressing et al., 2003, 2005) based on TCR:MHC class II crystal
structures (Hennecke et al., 2000; Hennecke and Wiley, 2002;
Reinherz et al., 1999). Thus, binding of gp42 to HLA is not only
necessary for viral entry but also may play a role in EBV immune
invasion.
gp42 forms a multimer in the crystal structure of unbound gp42
(Kirschner et al., 2009) and a dimer in the crystal structure of gp42
when bound to HLA class II (Mullen et al., 2002). Although the precise
interface between these two forms differ, they share a key region of
gp42 that is important in both forms for gp42 self-association. In the
unbound form, the N-terminal region extends away from the gp42
core and contacts an adjacent gp42 molecule, making interlayer
connections in the crystal lattice. Residues 87–93 in one gp42 interact
with residues 104–111 and 154–155 of an adjacent gp42 (Fig. 1A). In
the bound crystal structure, two gp42 molecules bound to two HLA
class II molecules contact each other. The N-terminal residues 87–94
of both gp42 molecules form a symmetric antiparallel two-stranded β
sheet and residue F88 of one gp42 molecule docks into a shallow
hydrophobic pocket on the CTLD surface of the adjacent gp42, formednd 87–93 (green), also residues W125, F129, and Y167 (cyan) are displayed as sticks.
one gp42 interacts with residues 104–111 and 154–155 (red) of an adjacent gp42. The
–222, colored blue-gray), and chain B (residues 76–222, colored wheat). (B) gp42:HLA
wo gp42 molecules form a symmetric antiparallel two-stranded beta sheet (green) and
ket on the CTLD surface of the adjacent gp42, formed byW125, F129 and Y167 (cyan and
us of each molecule is labeled N.
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surrounding F88, are key in the self-association of gp42 observed in
the two crystal forms of gp42 in the absence of HLA class II and in the
presence of HLA class II.
Deletion of portions of the putative dimerization domain or point
mutations at residue F88 reduces the fusion activity of gp42
(Kirschner et al., 2007, 2009). These studies demonstrate that the
region encompassing the F88 region is critical for gp42 function,
however whether this phenotype is attributable to a loss of multi-
merization or dimerization is unknown since this was not analyzed in
earlier studies. Interestingly, conformational differences between the
bound and unbound forms of gp42, speciﬁcally movement of the “158
loop” towards HLA class II in the bound form (Kirschner et al., 2009),
results in widening of the canonical CTLD binding pocket. Changes in
gp42 dimerization upon binding HLA class II may contribute to this
conformational change and potentially promote the interaction of the
gp42 binding pocket with gH/gL or an unknown ligand to trigger the
core fusion machinery of gH/gL and gB. Thus far, gp42 dimers have
never been detected and puriﬁed soluble gp42 is monomeric in
solution when analyzed in the absence of HLA class II by gel ﬁltration
chromotography (Kirschner et al., 2006). Our study sought to
investigate the interesting possibility of gp42 multimerization and/
or dimerization and determine if this gp42 self-association occurs in
the presence of HLA class II, with or without the gH/gL complex, and if
it is important for EBV fusion and entry.
Results
Construction of gp42 ﬂag tagged mutants
Several EBV gp42 functional domains have been characterized
previously, including a transmembrane domain, a gp42 cleavage site,
two gH/gL binding regions separated by a linker, and the C-terminal
C-type lectin domain (CTLD) which binds HLA class II (Fig. 2A).transmembrane 
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Fig. 2. Schematic representation of wild type gp42 and gp42 Flag-tagged mutants. (A) Appr
domain (residues 9–22), gp42 cleavage site (residues 40–42), the two gH/gL binding region
lectin domain (CTLD) which is responsible for binding HLA class II. The hydrophobic pocket
have the N-term 36 a.a of gp42 deleted, thus deleting the transmembrane domain and rende
putative self-association site.Previous studies have shown that deletion of the ﬁrst 36 residues of
gp42, including the transmembrane domain, creates a soluble form of
gp42 which is efﬁciently expressed and secreted and mediates B cell
fusion in cell–cell fusion assays, whereas a cleavage mutant in which
residues 37–41 are deleted does not (Sorem et al., 2009). Therefore, to
study whether the putative gp42 region, spanning amino acids 87–93,
is involved in self-association of gp42 molecules, as suggested by
X-ray crystallography (Figs. 1A and B), we ﬁrst constructed soluble
N-terminal variants of gp42 incorporating the Flag epitope. Mutant
d36Flag has the ﬁrst 36 residues of gp42 replaced with the Flag tag but
is otherwise wild type (Fig. 2B). We chose to use the d36 mutant since
our earlier studies had shown that this mutant retained full fusion
function and the presence of the N-terminal Flag tag provided a
convenient means to monitor expression and binding to gH/gL. Since
residues 87–93, and in particular residue F88, were shown in the gp42
unbound and gp42:HLA class II structures to mediate gp42 self
association (Figs. 1A and B), we generated the mutant F88AFlag and
d87-93Flag to study this in more detail. F88AFlag is identical to d36Flag
with the exception of one point mutation at residue 88 from a
phenylalanine to an alanine. d87-93Flag is identical to d36Flag with the
exception of a deletion spanning the entire putative dimerization
domain.
Gp42 mutants are expressed and secreted into the supernatant
To ensure that the ﬂag tagged gp42mutants were expressed similar
to wild type gp42 and produced soluble forms of gp42, each of the
mutants was transfected into CHO-K1 cells and their expression was
analyzed 48 h post-transfection by Western blot. We found that all of
the ﬂag tagged gp42 mutants were expressed and secreted into the
supernatant, as determined by probing with both an anti-ﬂag antibody
and an anti-gp42 antibody (Figs. 3A and B). Soluble gp42 and the gp42
mutants were readily detected in media supernatants as well as cell
lysates, presumably as intracellular protein undergoing transport to theC-type lectin domain (CTLD)  
  161    210                                 223
HP 
HLA binding residues 
                HP                          
                                                                                            223
                HP                          
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                                                                                            223
                                                                                            223
oximate location of gp42 functional domains are shown including the transmembrane
s (residues 47–61 and 67–81) separated by a linker region, and the C-terminal C-type
is indicated by HP. (B) gp42 Flag tagged mutants, d36Flag, F88AFlag and d87-93Flag, all
ring them secreted forms of gp42. F88AFlag is a point mutant, d87-93 deletes the entire
Fig. 3. gp42 mutants are expressed and secreted into the supernatant. CHO-K1 cells were transiently transfected with empty vector (pCAGGS and pCMV-Flag), wild type gp42, d37-41
gp42, d36Flag, F88AFlag and d87-93Flag. Forty eight hours post transfection supernatant was collected and cells were lysed in Triton X-100 lysis buffer containing protease inhibitors. Cell
lysates and culture supernatants were analyzed by 12% SDS-PAGE and Western blotting with (A) polyclonal anti-Flag antibody (F7425-Sigma) and (B) polyclonal anti-gp42 antibody
(PB114). Size markers in kDa are noted to the left of the blots.
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5–7 with lanes 12–14). All forms of gp42 displayed some heterogeneity
in size compatible with gp42 being glycoslyated. The cell lysates of wild
type gp42 and d37-41 showed a broader size range compared to the
mutants, reﬂective of retention of the various glycosylated forms of
gp42 by the transmembrane domain (compare Fig. 3B, lanes 2–3 with
5–7). However, the difference in glycosylation was not as signiﬁcant in
the supernatant, likely due to the fact that the soluble products
represent fully glycosylated gp42 (compare Fig. 3B, lane 9 with lanes
12–14). As predicted, d87-93 migrated faster than the other Flag
mutants due to deletion of amino acids 87–93 (Figs. 3A and B lane 7 and
14). Previous work has shown wild type gp42 is inefﬁciently cleaved,
resulting in some gp42 being bound at the cell surface and some being
soluble (Fig. 3B, lane 2 and 9). This was also readily observed in our
experiments. Themutant d37-41,which lacks the cleavage site, remains
entirely in cell lysates (compare Fig. 3B, lane 3 and 10), similar to our
previous ﬁnding (Sorem et al., 2009). This mutant is a useful tool for
studying whether dimerization of gp42 can occur at the cell surface
when gp42 is not cleaved.
Deletion of residues 87–93 alters cell–cell fusion
To study the effect of gp42 N-terminal truncation and replacement
with a Flag tag on membrane fusion with B cells, CHO-K1 cells
transfected with gB, gH/gL, and wild type or Flag tagged gp42 were
overlaid with Daudi cells. CELISA (Cell-based Enzyme-Linked Immu-
nosorbent Assay) analysis showed all of the soluble Flag tagged
mutants are present at the cell surface at wild type levels when co-
expressed with gH/gL, thus conﬁrming their ability to bind gH/gL,
which tether these soluble proteins to the cell (Fig. 4A). In the absence
of gH/gL, the Flag-taggedmutants did not bind to the cell surface (data
not shown), as expected from our previous studies (Sorem et al.,
2009). Whereas d36Flag had a modest 20% decrease in cell–cell fusioncompared to wild type gp42, F88AFlag had a 40–50% decrease in
fusion and d87-93Flag was severely impaired, exhibiting an approx-
imately 90% reduction in its ability to mediate fusion (Fig. 4B). Our
data is consistent with fusion data obtained for the untagged version
of F88A (Kirschner et al., 2009) and the untagged version of a similar
deletion mutant, d87-91, (Kirschner et al., 2007). As in our case, the
reduced fusion of these untagged versions was not due to a defect in
gH/gL binding.
Secreted gp42 mutants bind gH/gL but are not able to bind wild type
gp42 nor cleavage mutant gp42 (d37-41), when added exogenously
To assess the abilities of the secreted gp42 ﬂag mutants to bind
(dimerize or multimerize) wild type gp42 or cleavage mutant gp42
(d37-41), we performed a monolayer binding assay in which
exogenously expressed and normalized protein produced from each
of the ﬂag tagged mutants (d36Flag, F88AFlag and d87-93Flag) was
overlaid for 1 h at 4 °C on CHO-K1 monolayers transfected with wild
type gp42, d37-41 or gH/gL. Western blot analysis of the cell lysates,
including any bound proteins, with anti-ﬂag antibody showed all of the
ﬂag tagged gp42 mutants, regardless of the point mutation at residue
F88 or deletion 87–93, were able to bind gH/gL (Fig. 5A), as expected,
since the gH/gL binding sites are retained in these mutants. However,
d36Flag was not able to stably bind wild type gp42 nor was it able to
stably bind cleavage mutant gp42 (d37-41) (Fig. 5A, d36Flag),
suggesting soluble gp42 does not form dimers or multimers with
membrane bound gp42. Similar results were foundwhen F88AFlag and
d87-93Flag were overlaid on transfected cells; binding to gHgL was
detected but no binding to wild type gp42 nor membrane bound gp42
could be detected (Fig. 5A, F88AFlag and d87-93Flag). If dimerization or
multimerization occurred, we would have expected d36Flag to bind to
gp42, F88AFlag to have reduced dimerization and d87-93Flag to be
greatly altered in dimerization ability. In a control duplicate blot probed
Fig. 4. Secreted mutants bind gH/gL. Mutation or deletion of the gp42 putative
dimerization site reduces fusion in B cells. (A) Surface expression of gp42 constructs co-
transfectedwith gH, gL, and gBmeasured by CELISA usingmonoclonal anti-gp42 antibody
(3H3), secondary biotinylated anti-mouse IgG antibody, tertiary streptavidin–HRP and
TMB substrate. Color development was measured by absorbance at 370 nm. Cell surface
expression was normalized to wild type levels, which were set to 100%. Data shown are
representative results of three independent experiments. (B) Fusion of Daudi cells (target)
overlayed with CHO-K1 cells (effector cells) co-transfected with gp42 mutant constructs,
gH, gL and gB. Luciferase activity was normalized to wild type levels. Data shown are
representative results of three independent experiments. Error bars represent standard
deviations for the normalized values.
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wild type gp42 and cleavagemutant gp42 (d37-41) protein, suggesting
the inability of the soluble forms of gp42 to bindmembrane bound gp42
was not due to insufﬁcient gp42 at the cell surface.Gp42 mutants bind HLA class II at the cell surface but are not able to bind
wild type gp42 nor cleavage mutant gp42 (d37-41) when co-expressed in
cells
We next investigated whether soluble gp42 binds membrane
bound gp42 or HLA class II at the cell surface when expressed
endogenously and analyzed by CELISA using anti-Flag antibody. CHO-
K1 cells were co-transfected with each of the soluble mutants and
either wild-type gp42, d37-41 gp42 or HLA class II. We found that
d36Flag, F88AFlag and d87-93Flag had similar abilities to bind HLA,
however, in agreement with the monolayer binding assay, none of the
soluble proteins could bind wild-type gp42 or d37-41 gp42 (Fig. 6),
indicating that soluble gp42, when co-expressed with a membrane
bound form of gp42, is not able to bind membrane bound gp42 at the
cell surface. A duplicate CELISA using anti-gp42 antibody showedapproximately equal levels of gp42 in all but the vector alone
transfections (data not shown).
Gel ﬁltration analysis of gp42–gH/gL–HLA-DR1 complex formation
Previous data has shown that the soluble forms of gp42 and gHgL
form a stable complex with a ratio of 1:1 by gel ﬁltration analysis
(Kirschner et al., 2006).We sought to determine whether the addition
of soluble HLA class II may be important for gp42 self-association.
Soluble forms of gp42 (residues 33–223), gH (residues 18–679) and
gL (residues 24–137) were expressed and puriﬁed as previously
described (Kirschner et al., 2006) (Mullen et al., 2002). HLA-DR1
(residues 1–192 of theα chain and residues 1–198 of the β chain) was
expressed in S2 insect cells and puriﬁed as previously described
(Sloan et al., 1995). A2 peptide derived from HLA-A2 was loaded in
the peptide binding grove of HLA-DR1, as this peptide is known to be a
predominant peptide bound to HLA-DR1 in B cells (Murthy and Stern,
1997).
Puriﬁed and concentrated gp42, gH/gL and HLA-DR1 proteins were
initially injected on an S200 gel ﬁltration column individually to
conﬁrm the molecular weight of each protein compared to known
molecular weight standards run simultaneously. The gH/gL complex,
which is stable under physiological conditions, was expressed and
puriﬁed together and as a result was injected as a complex. gp42 was
observed at a retention volume corresponding to 43 kDa (yellow),
HLA-DR1 at 62 kDa (blue), and gHgL at 116 kDa (magenta), consistent
with their predicted molecular weights (Figs. 7A–C, and Table 1).
Next, gp42 and HLA-DR1 were combined at a 2:1 molar ratio
(gp42:HLA-DR1). After a 2 h incubation at room temperature the
combined sample was loaded onto the S200 column (Figs. 7A and C,
green line). We observed two elution peaks, one at 106 kDa (Fig. 7A,
peak 1 and Table 1), consistent with one gp42 bound to one HLA-DR1
in a 1:1 molar ratio and a second peak at 42 kDa (Fig. 7A, peak 2 and
Table 1), consistent with gp42 monomers. Because gp42 was added in
excess, we did not observe a peak for HLA-DR1 alone. We conﬁrmed
by Western blot that elution peak 1 contains both gp42 and HLA-DR1
(data not shown). The stability of the gp42:HLA-DR1 complexes
appears greater than previously observed (Mullen et al., 2002), which
may be due to differences in the DR1-bound peptide, which could
indirectly affect the gp42 binding afﬁnity, or in the expression source
of the HLA-DR1 protein.
We next combined gp42 with gH/gL at a 1:1 molar ratio and
incubated for 2 h at room temperature as before. We observed one
elution peak at 166 kDa (Figs. 7B and C, cyan line and Table 1), which is
consistent with gp42 complexingwith gHgL in a 1:1 molar ratio similar
to previously published data (Kirschner et al., 2006).We conﬁrmed that
this eluted fraction contained gp42 and gH/gL by coomassie stained
SDS-PAGE (data not shown).
Finally, gH/gL, gp42, andHLA-DR1proteinswere combined at a 1:1:1
molar ratio, incubated at room temperature for 2 h and loaded onto the
S200 column. We observed one main elution peak corresponding to
217 kDa (Fig. 7C, brown line and Table 1),which is consistentwithgp42,
gHgL, and HLA-DR1 complexing in a 1:1:1 molar ratio. Because gp42
complexed with HLA-DR1 as a dimer would be predicted to have an
apparent molecular weight close to 217 kDa, we conﬁrmed that the
eluted fraction contained gp42, gH/gL and HLA-DR1 by Coomassie
stained SDS-PAGE (data not shown). Our data shows the addition of
HLA-DR1 protein does not alter the 1:1 stoichiometry of gH/gL:gp42.
Thus, we were unable to detect any gp42 dimers or multimers in any of
the conditions tested using soluble forms of the relevant proteins,
indicating that either dimerization ormultimerization does not occur or
it occurs only transiently and/or with low afﬁnity such that they are not
readily detected in solution by gel ﬁltration.
Native gel analysis of CHO-K1 cells transfectedwith gp42 expression
vector (wild type gp42 and the gp42 mutants d36Flag, F88AFlag, d87-
93Flag),with orwithoutHLA class II, showed that themutations in gp42
Fig. 5. Secreted gp42 mutants bind gH/gL but not wild type gp42 nor gp42 cleavage mutant d37-41. CHO-K1 cells were transiently transfected with d36Flag, F88AFlag and d87-
93Flag. Secreted protein was isolated 48 h post transfection, normalized by Western Blot and then overlayed onto CHO-K1 cells transiently transfected with WT-gp42, d37-41 gp42,
or gH/gL for 1 h at 4 °C. Cells were washed, lysed with Triton X-100 and analyzed by 12% SDS-PAGE andWestern blotting with A) polyclonal anti-ﬂag antibody (F7425-Sigma) and B)
polyclonal anti-gp42 antibody (PB114). Size markers in kDa are noted to the left of the blots. Data shown are representative results from two independent experiments.
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Wild type gp42 and each of the gp42 mutants bound HLA class II and
produced a slower migrating complex. The complex was absent when
HLA class II was co-expressed with a previously described gp42 point
mutant (Y107A) that does not bindHLA class II (Silva et al., 2004). Thus,
the slower migrating complex is consistent with a 1:1 association of
gp42:HLA, as seen by gel ﬁltration.Discussion
EBV infects B cells via the fusion complex of gp42-gH/gL-gB. While
it is clear that gH requires gL for export to the cellular membrane
(Pulford et al., 1995; Yaswen et al., 1993), it is not clear if the other
EBV glycoproteins are complexed together within the cell or
alternatively if the fusion complex is formed at the cellular membrane
prior to envelopment. It is known that gp42 complexes with gH/gL
through its N-terminus and with its receptor, HLA class II, through its
CTLD. However, whether the gH/gL binding site on gp42 changes after
HLA class II binding is not clear. In addition, X-ray crystallography data
(Kirschner et al., 2009; Mullen et al., 2002) suggested that gp42 may
form multimers in the absence of HLA class II or dimers after
engagement with HLA class II. Crystal structures of gp42, both bound
and unbound to HLA, indicated that residues 87–93 and F88, in
particular, may be important contact residues for multimerization or
dimerization, providing the basis for our studies (Figs. 1A and B).
Using tagged mutants of gp42, we show that when gp42 is
expressed endogenously or added to cells exogenously, it does not
form dimers at the cell surface, in the absence of HLA. The inability to
dimerize is not due to a loss of ability to bind gH/gL or HLA class II.
In the presence of HLA class II, a complex was detected for wild
type gp42 as well as for the tagged mutants regardless of mutation of
the putative multimerization or dimerization site. This complex likely
represents a 1:1 complex of gp42 and the HLA class II heterodimer.
The fact that the complex is detected for d87-93Flag suggests that
gp42 does not dimerize, or, alternatively, that gp42 dimerization is
not dependent on the predicted site. In addition, our data show that
the presence of gH/gL does not promote gp42 self-association
formation.Previously, puriﬁed soluble forms of gH/gL and gp42were found to
associate in a 1:1 stoichiometry (Kirschner et al., 2006). We sought to
determine if binding to HLA class II would change this stoichiometry.
The size of the gH/gL–gp42–HLA-DR1 elution complex determined by
gel ﬁltration of puriﬁed soluble proteins was 217, consistent with a
1:1:1 ratio of glycoproteins to receptor. We were unable to detect
gp42 dimers or multimers in solution regardless of the presence of
HLA. Thus, our data strongly suggest that the dimers or multimers
observed in the gp42 crystal structures are likely the result of crystal
packing. However, we have not ruled out the possibility that gp42
may dimerize with low afﬁnity or transiently upon HLA binding and
therefore is undetectable by our methods.
Interestingly, herpes simplex virus (HSV) gD, a functional homolog
of gp42, masks it own receptor binding site as a part of its fusion
triggering mechanism. Like gp42, gD binds a receptor and acts to
trigger fusion mediated by HSV gH/gL and gB. Crosslinking studies
with HSV virions have suggested that gD is oligomeric in the absence
of its receptor (Handler et al., 1996). In addition, gel ﬁltration
chromatography data have suggested gD may form dimers in the
presence of its receptor (Whitbeck et al., 1997). In contrast, gD
crystallized as amonomer, both on its own andwhen bound to HVEM,
however the C-terminus was truncated to produce the puriﬁed
protein (Carﬁ et al., 2001). The introduction of a disulﬁde bond at the
C-terminus of the gD ectodomain stabilized a dimer form of gD. The
crystal structure shows dimerization contacts within the C-terminal
region, proximal to the membrane (Krummenacher et al., 2005).
Comparison of the structures of gD alone and in complex with its
receptor, HVEM, demonstrate that prior to receptor binding, the C-
terminus of gD masks its receptor binding site (Krummenacher et al.,
2005). Upon receptor binding, this C-terminus, termed the pro-fusion
domain, is displaced and upon its release, it interacts with gH/gL and/or
gB to trigger fusion.
gp42 is a type II protein and thus its N-terminus (membrane
proximal prior to cleavage) is positionally analogous to the C-terminal
region of type I protein gD (although gD is not cleaved). The
crystallographic multimerization of unbound gp42 is asymmetric
with residues 87–93 from one gp42 contacting residues 104–111, 154
and 155 in another gp42, which coincides with the HLA binding site
(Figs. 1A and B). One might postulate from these crystal data that the
Fig. 6. gp42 mutants bind HLA but not wild type gp42 nor the cleavage mutant d37-41.
Binding of soluble gp42mutants was determined by CELISA using monoclonal anti-Flag
antibody (F1804-Sigma), secondary biotinylated anti-mouse IgG antibody, tertiary
streptavidin–HRP and TMB substrate. Color development was measured by absorbance
at 370 nm. Cell surface expression was normalized to HLA binding, which was set to
100%. (A) d36Flag co-transfected into CHO-K1 cells with vector alone, wild type gp42,
d37-41 gp42 or HLA. (B) F88AFlag co-transfected into CHO-K1 cells with vector alone,
wild type gp42, d37-41 gp42 or HLA. (C) d87-93Flag co-transfected into CHO-K1 cells
with vector alone, wild type-gp42, d37-41 gp42 or HLA. Data shown are representative
results from three independent experiments. Error bars represent standard deviations
for the normalized values.
Fig. 7. Gel ﬁltration elution traces (overlaid) showing the soluble gp42–gH/gL–HLA-DR1,
complex in a 1:1:1 ratio as determined by size. (A) Elution traces of gp42 (yellow, Peak 4),
HLA-DR1 (blue, Peak 3), and gp42–HLA-DR1 complex (2:1 mixture, green, Peak 1 and 2).
(B) Elution traces of gp42 (yellow), gH/gL (magenta), and gH/gL–gp42 complex (1:1:1
mixture, cyan). (C) Elution traces of gp42 (yellow), HLA-DR1 (blue), gp42–HLA-DR1 (2:1
mixture, green), gH/gL (magenta), gH/gL–gp42(1:1mixture, cyan) andgH/gL–gp42–HLA-
DR1complex (brown) are overlaid. The soluble gH/gL–gp42–HLA-DR1 complex (indicated
by arrow) corresponds to a 1:1:1molar ratio. Elution of each protein from an S200 column
was monitored with 280 nm absorbance unit.
Table 1
Soluble protein(s) injected on S200 gel ﬁltration column, their retention values and
calculated molecular weights. Each molecular weight value was calculated using the
equation y=−0.2026x+4.3768 where y is log10 of the molecular weight (in kDa) and
x is the retention (in ml). The equation was calculated using 8 different protein samples
with known molecular weight distributed between 670 and 13.7 kDa.
Protein Retention (ml) Calculated molecular weight (kDa)
gHgL–gp42–HLA-DR1 10.07 217.08
gHgL–gp42 10.65 165.62
gp42–HLA-DR1 11.61 105.83
gHgL 11.41 116.18
HLA-DR1 12.75 62.18
gp42 13.54 43.01
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region of the neighboring gp42. Binding of HLA class II to gp42 could
be postulated to displace the gp42 N-terminal extension of the
neighboring gp42, thereby dissolving the gp42 self-association and
releasing the gp42 N-terminal extension. This freshly released gp42
N-terminal extension, including residue F88, could then serve as a
signal to trigger fusion by binding symmetrically to another gp42 as
found in the gp42 crystal structure when bound to HLA class II.Other than the crystallographic data, however, we have not been
able to show gp42 dimer formation. Therefore, it is unlikely that gp42
binding to HLA dissociates gp42 dimers. Further evidence that gp42
doesnotmask its own receptor binding site is that theF88Amutant does
not show increased binding to HLA. For HSV, a mutation gD-W294A
reduces the binding of the gDC-terminus to the gD receptor binding site
and results in increased receptor binding afﬁnity. Since the unbound
gp42 dimer structure shows F88 interacting with the HLA site, the fact
that F88A does not alter HLA binding is further evidence against a
functional role for these dimeric contacts.
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reduced level of fusion seen for the gp42 F88A and d87-93 mutants is
due to another defect in the proteins. Both gp42 mutants retain their
ability to bind to gH/gL and HLA, however they are unable to trigger
fusion. Perhaps gp42 residues 87–93 are responsible for transmitting
an activation signal to the gH/gL complex. These residues lie
downstream of the deﬁned gH/gL interaction site, but they could
function to activate gH/gL after binding. Alternatively, these residues
could be involved in triggering a conformational change in gB to drive
fusion. Future experiments are needed to further evaluate these
possibilities.
Methods
Cells and antibodies
Mammalian cells were grown in 25-cm2 or 75-cm2 cell cultureﬂasks
(Corning) in medium supplemented with 10% FetalPlex animal
serum complex (Gemini Bio-Products) and 1% penicillin–streptomycin
(BioWhittaker). Mammalian B cells were Daudi lymphocytes that are
EBV positive, express HLA class II and CD21 (American Type Culture
Collection), andaremodiﬁed to stably express T7RNApolymeraseunder
selection of G418 (700 μg/ml) in RPMI 1640 medium (BioWhittaker)
(Silva et al., 2004). Chinese hamster ovary K1 (CHO-K1) cells were
grown in Ham's F-12 medium (BioWhitaker). Trypsin-Versene (Bio-
Whittaker) was used to detach adherent cells. Polyclonal anti-gp42
antibody serum (PB114) was used as previously described (McShane et
al., 2003). Monoclonal antibody 3H3 (anti-gp42) was obtained as
previously described (Kirschner et al., 2006). Monoclonal anti-Flag M2
antibody (F1804) and polyclonal anti-Flag antibody (F7425) were
obtained from Sigma-Aldrich Chemical Company.
Plasmids
Gp42 mutant d37-41 was described previously (Kirschner et al.,
2007; Sorem et al., 2009). Flag tagged gp42 (designated d36Flag) was
generated by PCR amplifying fromwild type gp42 (cloned into PCAGGS),
using primer 5′-GGAATTCCGTGGCAGCCGCGGCC-3′ and primer 5′-
CAGATCTGTTAGCTATTTGATCTTTGACTGAC-3′ resulting in deletion of
the ﬁrst 36 a.a. of gp42. The PCR product was puriﬁed by Qiagen PCR
puriﬁcation kit, digested with EcoRI and Bgl II, puriﬁed by Qiagen gel
extraction kit and ligated into the gel puriﬁed EcoRI- and Bgl II-digested
pFLAG-myc-CMV-21 expression vector (E5776; Sigma-Aldrich). Flag
tagged point mutant F88A (designated F88AFlag) was generated by PCR
amplifying from a gp42 F88Amutant that has been previously described
(Kirschner et al., 2009) using the same primers as above, resulting in
deletionof theﬁrst 36 a.a. of gp42.D87-93Fwas generatedby four primer
PCR using the primers 5′-GGAATTCCGTGGCAGCCGCGGCC-3′ and 5′-
CAGTTAGCTTTGGTATAGTGCAGGGTGGGTGTCC-3′ in one PCR reaction
and primers 5′-GGACACCCACCCTGCACTATACCAAAGCTAACTG-3′ and
5′-CAGATCTGTTAGCTATTTGATCTTTGACTGAC-3′ in another PCR reac-
tion in the ﬁrst round of PCR. Outside primers 5′-GGAATTCCGTGG-
CAGCCGCGGCC-3′ and 5′-CAGATCTGTTAGCTATTTGATCTTTGACTGAC-3′
were used in the second round of PCR to generate the deletion of amino
acids 87–93 which was then cloned into the EcoR I and Bgl II-digested
pFLAG-myc-CMV-21 expression vector, as described above.
PCR products were ligated overnight at 14 °C with pFlag-myc-
CMV-21 digested vector, transformed into DH5α, and selected on
ampicillin plates. Minipreparations were prepared from overnight
cultures using Qiagen miniprep kit, digested to conﬁrm the presence
of insert and sequenced by the Northwestern Genomic Core Facility.
Large scale preparations were isolated using Qiagen Endo-Free
Plasmid maxiprep kit and used in subsequent experiments.
HLA-DRα and HLA-DRβ008 were cloned into pSG5 (Stratagene) as
previously described (Haan et al., 2000).Transfection
CHO-K1 cells were transfected in Opti-Mem (Gibco) medium using
Lipofectamine 2000 (Invitrogen) according the manufacturer's direc-
tions. Brieﬂy, 24 h after plating in a sixwell dish, various combinations of
expression vectors were transfected with 6 μl of lipofectamine in Opti
Mem.
(i) CELISA and fusion (Fig. 4): pFLAG-myc-CMV-21 (vector) 4 μg,
wild type gp42 2 μg, d37-41 2 μg, d36Flag 2 μg, F88AFlag 2 μg,
d87-93Flag 2 μg, and gH 0.5 μg, gL 0.5 μg, gB 0.5 μg, T7 luciferase
0.8 μg
(ii) Expression analysis (Fig. 3): pCAGGS 4 μg, wild type gp42 4 μg,
d37-41 4 μg, pFLAG-myc-CMV-21 (vector) 4 μg, d36Flag 4 μg,
F88AFlag 4 μg, d87-93Flag 4 μg.
(iii) Monolayer binding assay (Fig. 5): pCAGGS 4 μg, wild type gp42
4 μg, d37-41 4 μg, gH 2 μg, gL 2 μg
(iv) CELISA assay (Fig. 6): pFLAG-myc-CMV-21 (vector) 4 µg, wild
type gp42 2 µg, d37-41 2 µg, HLA-DRα 1 µg, HLA-DRβ 1 µg,
d36Flag 2 µg, F88AFlag 2 µg, d87-93 2 µg.Western blotting
CHO-K1 cells were transfected as stated above. The medium was
changed 5–6 h post transfection to complete Ham's F12 medium and
cells and culture supernatants were collected at 48 h post transfec-
tion. Cells were detached with Versene, washed with PBS, and lysed
using a 1% Triton X-100 buffer containing protease inhibitors (1 ml of
lysis buffer/10 million cells). Culture supernatants were collected
prior to cell detachment and spun down to pellet detached cells.
Supernatants and lysates were run on 12% Bio-Rad Criterion gels in
sodium dodecyl sulfate (SDS) sample buffer at 90 V for l.5 h. Proteins
were transferred to Whatman Optitran 0.45 μm nitrocellulose
membrane in transfer buffer at 100 V for 90 min. Blots were blocked
in Tris-buffered saline with 5% milk for 1 h at room temperature or
overnight at 4 °C and then incubated for 2 h at room temperaturewith
polyclonal anti-ﬂag antibody (Sigma, F7425) 1:1000 or polyclonal
anti-gp42 antibody serum (PB114) 1:2000 in blocking solution, as
previously described (Fan and Longnecker, 2010; McShane et al.,
2003). Blots were washed and horseradish peroxidise (HRP)
conjugated anti-rabbit immunoglobulin G (Cell Signaling) was
applied for 1.5 h at room temperature. The blots were washed and
overlaid with equal volumes of ECL Western blotting detection
reagents (GE Healthcare) and exposed to hyperﬁlm (Amersham
Biosciences).Cell enzyme-linked immunosorbent assay (CELISA)
CELISAwas used to test the cell surface expression. Brieﬂy, CHO-K1
cells were co-transfected in a 6 well dish with each of the Flag tagged
mutants and either wild-type gp42, d37-41, HLA or empty vector. The
medium was changed 5–6 h post transfection. Twenty-four hours
post transfection the cells were detached with Versene, counted using
a Beckman Coulter Z1 particle counter, 37,500 cells were transferred
to a 96 well plate and the total volume was adjusted to 150 μl with
complete Ham's F12 medium. Twenty-four hours later cells were
washed once with phosphate-buffered saline (PBS), and CELISA was
performed using the monoclonal antibody anti-FLAG-M2 (F1804;
Sigma). After incubation with antibody, the cells were washed, ﬁxed,
and incubated with biotinylated goat anti-mouse IgG (Sigma),
followed by streptavidin–horseradish peroxidase (HRP) (GE Health-
care) and TMB one component HRP substrate (BioFX). Absorbance
readings were taken at 380 nm using a Wallac-Victor luminometer
(Perkin-Elmer).
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CHO-K1 cells were transiently transfected as described above. The
medium was changed 5–6 h post transfection and 24 h post
transfection the cells were detached with Versene and 37,500 cells
were transferred to duplicate 96-well plates, one plate was used for
CELISA with monoclonal anti-gp42 antibody (3H3) and the other
plate was overlaid with equal numbers of Daudi B-target cells. The
total volume was adjusted to 150 μl with complete Ham's F12
medium. Eighteen to 20 h after overlay, cells were washed with PBS
and lysed for 10 min with 50 μl passive lysis buffer (Promega) per
well. Luciferase activity was measured with a Perkin-Elmer Victor
plate reader immediately after addition of 50 μl/well of luciferase
reagent (Promega).
Monolayer binding assay
A “monolayer binding assay”was performed as previously described
(Fan and Longnecker, 2010) to assess the abilities of the secreted gp42
ﬂag mutants to bind wild type gp42 or transmembrane bound gp42.
CHO-K1 cells seeded in six well plates for 24 h were transfected with
wild type gp42, d37-41, gH/gL or HLA using 6 μl of Lipofectamine 2000.
After 24 h of incubation, the cells were washed twice with cold PBS and
incubated with each of the ﬂag mutant protein (isolated following 48 h
transfection and normalized to each other by Western blot, data not
shown) for 1 h at 4 °C. The cells were then washed with cold PBS four
times and lysed with 200 μl of lysis buffer (25 mM Tris–HCl [pH 7.4],
150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM Na3VO3, 1% Nonidet
P-40) containing a protease inhibitor mixture (Roche Diagnostics).
Proteins were separated on Bio-Rad Criterion 12% SDS-PAGE gels after
boiling for 10 min under reducing conditions. Western blot analyses
were performed using the polyclonal anti-Flag antibody (F7425) at
1:1000 and polyclonal anti-gp42 antibody serum (PB114) at 1:2000.
Expression and puriﬁcation of soluble proteins
HLA-DR1
Soluble HLA-DR1 fromDRA*0101 and DRB1*0101 genes (Sloan et al.,
1995) were produced as empty αβ heterodimers secreted from stably
transfected S2 Schneider cells. Protein expression was induced with
1 mM CuSO4 and the cell supernatant was collected after 5–6 days. The
supernatant was centrifuged, ﬁltered through 0.22 μm membrane and
loadedonto L243antibody column. Puriﬁcationwasdonebywashing the
column with PBS and eluting with CAPS pH 11.5 buffer, following with
immediate neutralizationwith 1 Msodiumphosphate pH6.0. PeptideA2
derived fromHLA-A2(residues103–117)wasbound to thepuriﬁedHLA-
DR1 protein with 2–10 fold molar excess peptide. The HLA-DR1 and A2
peptidemixturewas incubated at 37 °C for 72 h in the presence of 1 mM
EDTA, 1 mM PMSF, 0.1 mM iodoacetamide, and 3 mM NaN3 in PBS.
Excess peptide was removed by using a 10 kDa centrifugal ﬁlter unit
(Amicon Ultra-15, Millipore) and the peptide loaded HLA-DR1 was
concentrated to 10 mg/ml and stored at 4 °C.
gp42 and gHgL
Soluble gHgL and gp42 was expressed and puriﬁed as previously
described (Kirschner et al., 2006) (Mullen et al., 2002). Brieﬂy, residues
33–223 of gp42 containing a 6His-tag, S-tag, and an enterokinase
cleavage site at the N-terminus were expressed in Hi-5 insect cells
infected with ampliﬁed recombinant baculovirus. Cell supernatant
containing gp42 protein was collected by centrifugation after 72 h of
incubation and sterileﬁltered. Initial puriﬁcationwasdoneusing a Talon
metal afﬁnity resin (Clontech) following themanufacturer's manual for
batch puriﬁcation. Enterokinase was used to cleave the tags. Concen-
tratedgp42 samplewas further puriﬁedbyS75 gelﬁltration column(GE
Healthcare) in 25 mM Tris pH 7.4, 150 mM NaCl (TBS), buffer.Residues 18–279 of gH and residues 24–137 of gL were expressed
simultaneously as secreted proteins using pBACgus4x-1 (Novagen)
baculovirus transfer plasmid containing two promoters. Sf+ insect
cells were used for protein expression. Cell supernatant was collected
by centrifugation at 72 h post infection with ampliﬁed baculovirus
stock. Sterile ﬁltered supernatant containing gHgL was puriﬁed using
E1D1 antibody afﬁnity column and eluted with 0.1 M sodium citrate
pH2.5, immediately neutralized by adding 1 M sodium citrate tribasic
salt and 5 M NaCl to be ﬁnally pH 5.5. E1D1 antibody hybridoma was
provided to us by L. Hutt-Fletcher. Concentrated gHgL was applied to
S200 gel ﬁltration column (GE Healthcare). 50 mM sodium citrate
pH5.5 and 50 mM NaCl was used for the ﬁnal puriﬁcation step.
Gel ﬁltration chromatography
Puriﬁed HLA-DR1 loaded with A2 peptide, gp42, and gHgL proteins
were each concentrated and buffer was exchanged into TBS. S200 gel
ﬁltration column was connected to an AKTA puriﬁer (GE Healthcare)
and absorbance of 280 nmwasmonitored. To create a calibration curve
to estimate the relation between the elution volume and molecular
weight, the S200 column was equilibrated with TBS buffer and
molecular weight markers thyroglobulin (669 kDa), apoferritin
(443 kDa), beta-amylase (200 kDa), alcohol dehydrogenase
(150 kDa), albumin (66 kDa), ovalbumin (43 kDa), carbonic anhydrase
(29 kDa) and ribonuclease A (13.7 kDa) (Sigma) were combined into
two separate injections and loadedonto the column. The elution volume
of eachprotein samplewasmonitored at aﬂow rate of 0.6 ml/min. HLA-
DR1, gp42, and gHgL proteins were injected individually and as
complexes at 0.5 ml/min or 0.6 ml/min in TBS. Eluted samples were
collected as 0.5 ml fractions.
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